Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
about
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffeeEffects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-AnalysisAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysisNeurobehavioral testing in human risk assessmentCreatine for Parkinson's diseaseCreatine for Parkinson's diseaseLRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site statusCognition, language, and clinical pathological features of non-Alzheimer's dementias: an overviewDeep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's DiseaseNutraceuticals in Parkinson's DiseaseThe Interaction between Obstructive Sleep Apnea and Parkinson's Disease: Possible Mechanisms and Implications for Cognitive FunctionNeuroimaging studies of striatum in cognition part II: Parkinson's diseaseFriends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesCognitive Behaviour Therapy for Depression and Anxiety in Parkinson's DiseaseDeconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose'The clocks that time us'--circadian rhythms in neurodegenerative disordersThe Rationale for Exercise in the Management of Pain in Parkinson's DiseaseGlia and alpha-synuclein in neurodegeneration: A complex interactionThe role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelismPreservation of function in Parkinson's disease: what's learning got to do with it?Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian modelsPathologic and therapeutic implications for the cell biology of parkinMild cognitive impairment in Parkinson's disease.Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalitiesEfficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotypeTime to change the blind men and the elephant approach to Parkinson disease?Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future ProspectiveSystems biology of neurodegenerative diseasesTechnology for deep brain stimulation at a gallopMeeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Parkinson's disease research in a prospective cohort in ChinaBeyond mitophagy: cytosolic PINK1 as a messenger of mitochondrial healthPesticides, microglial NOX2, and Parkinson's diseaseSalvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease modelsMetformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine NeuronsPrecompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseNeurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish EmbryosAn update on the diagnosis and treatment of Parkinson disease
P2860
Q21092426-087D836D-7577-426C-87C4-AE2E42BF857FQ21131738-2614A7B1-F69E-40A4-A82D-3B6706C59D60Q22241651-6C47878D-1DD6-461A-B717-BC1D6241B8F5Q23912123-96A5E81E-4296-48CC-BFBD-2E5BEA342897Q24193947-0F2E2025-6613-4DFF-94BF-7263ABCAAFEDQ24203799-63A95FFF-B672-4424-A2EF-DA4C822A0BF9Q24300605-4441C8AE-3D37-4E18-AAB0-0C6228DC7399Q24631298-72B73F44-64E8-4810-AC85-774CFB01F585Q26747575-8B87F6F8-86B4-4162-99B4-F5089E7EECFAQ26752769-A929E546-CB00-4B98-B68C-4670D3F6FED5Q26778246-E67433F6-BF95-4597-9EF5-5F6E4AC43C9EQ26779306-2AD0865C-B1E8-4CB7-ABA0-31D8A59FFC64Q26779933-EB2F9499-F013-4B3D-A91B-A65EB1E85514Q26781122-BF4568C1-F45B-4029-B097-A29B4F623591Q26785491-332FF43C-D515-49D6-BE6A-19F41E42523BQ26824646-5D61F301-04D2-446A-894B-4CDBE7572476Q26828016-B2F40FF3-7252-477E-8477-53B2BF12C38AQ26851153-31354F9F-C4FA-4694-B8C7-C905E006022BQ26852148-8739A74E-9145-4140-A45D-DD15D04D2220Q26853387-45F85842-2585-4785-85D4-B8046E20F883Q26863375-EB38FDFF-64E4-4C14-82F5-3939940F2728Q27010567-F67238B7-6819-4461-A924-2A0769B2F458Q27021220-1E38EDF3-1170-45DB-B0A8-93E25235D246Q27021464-0CA0D5FA-390F-40C9-82B5-0C244C9DE3FCQ27023811-763449D8-48EB-4868-847A-5AC6CF2EB71AQ27304699-84176CC5-F9CA-4CCE-8777-4C78475427D5Q27333275-016B56A9-63B2-4014-BF95-90AD4F828034Q27693350-CB0664C6-5E50-404C-BD16-98C8EFB99FC3Q28075999-25F9DD46-540A-4DE1-BBA2-5A6A58278A9CQ28080741-7D338317-07A7-48C4-B140-23A125611E5AQ28081237-76FC8B06-6752-46D2-90DE-F67B77631B29Q28387116-4813CF4A-AA02-4A47-91C2-FDE459C76E10Q28389811-17D23BC5-487F-41AE-BAA6-A0666DE75B75Q28391455-A36C337E-0613-429D-ADF9-F244CCF3DB39Q28397585-10090127-E77B-48DB-9A35-424CC106D456Q28540349-9B909DD4-1B7E-4530-81AA-F2E4B6B85D57Q28553200-08761EA9-B044-46C0-B66B-3D55784D7652Q28601965-EDCA24D2-93EB-41E5-A29C-57A95BC6008BQ29541727-12177411-3200-4E17-89E6-D4D0F83C4289Q30243899-84B7A9A0-331D-438B-9A34-3B15B2E14C43
P2860
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Projected number of people wit ...... us nations, 2005 through 2030.
@en
type
label
Projected number of people wit ...... us nations, 2005 through 2030.
@en
prefLabel
Projected number of people wit ...... us nations, 2005 through 2030.
@en
P2093
P1433
P1476
Projected number of people wit ...... us nations, 2005 through 2030.
@en
P2093
Constantinescu R
Holloway RG
Kieburtz K
Marshall FJ
Schifitto G
Siderowf A
P304
P356
10.1212/01.WNL.0000247740.47667.03
P407
P577
2006-11-02T00:00:00Z